Genmab Gross Profit 2009-2021 | GNMSF

Genmab annual/quarterly gross profit history and growth rate from 2009 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Genmab gross profit for the quarter ending September 30, 2021 was $0.366B, a 35.36% increase year-over-year.
  • Genmab gross profit for the twelve months ending September 30, 2021 was $1.284B, a 22.22% decline year-over-year.
  • Genmab annual gross profit for 2020 was $1.549B, a 92.58% increase from 2019.
  • Genmab annual gross profit for 2019 was $0.804B, a 67.86% increase from 2018.
  • Genmab annual gross profit for 2018 was $0.479B, a 33.36% increase from 2017.
Genmab Annual Gross Profit
(Millions of US $)
2020 $1,549
2019 $804
2018 $479
2017 $359
2016 $270
2015 $169
2014 $152
2013 $118
2012 $84
2011 $66
2010 $104
2009 $113
2008 $137
2007 $104
Genmab Quarterly Gross Profit
(Millions of US $)
2021-09-30 $366
2021-06-30 $320
2021-03-31 $256
2020-12-31 $341
2020-09-30 $271
2020-06-30 $805
2020-03-31 $132
2019-12-31 $443
2019-09-30 $155
2019-06-30 $117
2019-03-31 $90
2018-06-30 $82
2018-03-31 $112
2017-12-31 $158
2017-09-30 $51
2017-06-30 $114
2017-03-31 $36
2016-12-31 $136
2016-09-30 $55
2016-06-30 $54
2016-03-31 $25
2015-12-31 $85
2015-09-30 $41
2015-06-30 $26
2015-03-31 $16
2014-12-31 $37
2014-09-30 $46
2014-06-30 $21
2014-03-31 $46
2013-12-31 $39
2013-09-30 $27
2013-06-30 $25
2013-03-31 $28
2012-12-31 $28
2012-09-30 $20
2012-06-30 $18
2012-03-31 $16
2011-12-31 $16
2011-09-30 $17
2011-06-30 $16
2011-03-31 $16
2010-12-31 $17
2010-09-30 $37
2010-06-30 $30
2010-03-31 $19
2009-12-31 $31
2009-09-30 $20
2009-06-30 $17
2009-03-31 $45
2008-12-31 $15
2008-06-30 $25
2008-03-31 $34
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $22.618B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00